275 related articles for article (PubMed ID: 31800729)
1. Retrospective analysis of efficacy, safety, and prognostic factors in a cohort of Chinese hepatocellular carcinoma patients treated with drug-eluting bead transarterial chemoembolization.
Chen S; Ji R; Shi X; Wang Z; Zhu D
Braz J Med Biol Res; 2019; 52(12):e8467. PubMed ID: 31800729
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
[TBL] [Abstract][Full Text] [Related]
3. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres
Peng Z; Cao G; Hou Q; Li L; Ying S; Sun J; Zhou G; Zhou J; Zhang X; Ji W; Yu Z; Li T; Zhu D; Hu W; Ji J; Du H; Shi C; Guo X; Fang J; Han J; Gu W; Xie X; Sun Z; Xu H; Wu X; Hu T; Huang J; Hu H; Zheng J; Luo J; Chen Y; Yu W; Shao G
Oncol Res; 2020 May; 28(3):249-271. PubMed ID: 31856933
[TBL] [Abstract][Full Text] [Related]
4. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
Zhang X; Lin X; Qiu H; Peng Z
J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
7. Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma.
Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Nakano M; Okamura S; Noda Y; Kamachi N; Sakai M; Suzuki H; Nomiyama M; Kuromatsu R; Koga H; Torimura T
Oncology; 2020; 98(8):558-565. PubMed ID: 32422633
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
Li H; Wu F; Duan M; Zhang G
Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
[TBL] [Abstract][Full Text] [Related]
9. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
Zhao C; Ma SPZCY
J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients.
Zhou GH; Han J; Sun JH; Zhang YL; Zhou TY; Nie CH; Zhu TY; Chen SQ; Wang BQ; Yu ZN; Wang HL; Chen LM; Wang WL; Zheng SS
BMC Cancer; 2018 Jun; 18(1):644. PubMed ID: 29914435
[TBL] [Abstract][Full Text] [Related]
11. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients.
Zhou Y
Int J Clin Exp Pathol; 2018; 11(10):4867-4878. PubMed ID: 31949562
[TBL] [Abstract][Full Text] [Related]
13. Survival, tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma.
Huo YR; Xiang H; Chan MV; Chan C
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):802-811. PubMed ID: 31709778
[TBL] [Abstract][Full Text] [Related]
14. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
Zhu D; Yuan D; Wang Z; Chen S
Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
[TBL] [Abstract][Full Text] [Related]
16. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
[TBL] [Abstract][Full Text] [Related]
17. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
18. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
[TBL] [Abstract][Full Text] [Related]
19. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
